Close Menu

NEW YORK (GenomeWeb) – Illumina said on Sunday that it has launched a new company called Grail, which will develop a next-generation sequencing blood-based screening test for early cancer detection.

Grail has raised more than $100 million in a Series A financing round from Arch Venture Partners and Illumina, which contributed $40 million. Bezos Expeditions, Bill Gates, and Sutter Hill Ventures also invested in Grail.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.